CI994 (Tacedinaline)HDAC inhibitor CAS# 112522-64-2 |
- RG2833
Catalog No.:BCC1893
CAS No.:1215493-56-3
- TMP269
Catalog No.:BCC3993
CAS No.:1314890-29-3
- M344
Catalog No.:BCC2162
CAS No.:251456-60-7
- LAQ824 (NVP-LAQ824,Dacinostat)
Catalog No.:BCC2160
CAS No.:404951-53-7
- NCH 51
Catalog No.:BCC2422
CAS No.:848354-66-5
- AR-42 (OSU-HDAC42)
Catalog No.:BCC2161
CAS No.:935881-37-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 112522-64-2 | SDF | Download SDF |
| PubChem ID | 2746 | Appearance | Powder |
| Formula | C15H15N3O2 | M.Wt | 269.3 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Acetyldinaline; Tacedinaline; PD 123654; Goe 5549 | ||
| Solubility | DMSO : ≥ 58 mg/mL (215.37 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 4-acetamido-N-(2-aminophenyl)benzamide | ||
| SMILES | CC(=O)NC1=CC=C(C=C1)C(=O)NC2=CC=CC=C2N | ||
| Standard InChIKey | VAZAPHZUAVEOMC-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C15H15N3O2/c1-10(19)17-12-8-6-11(7-9-12)15(20)18-14-5-3-2-4-13(14)16/h2-9H,16H2,1H3,(H,17,19)(H,18,20) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | CI-994 (Tacedinaline),an anti-cancer drug, is an inhibitor of HDAC1 with IC50 of 0.57 μM and causes G1 cell cycle arrest. | |||||
| Targets | HDAC1 | |||||
| IC50 | 0.57 μM | |||||
| Cell experiment: [1] | |
| Cell lines | Peripheral blood lymphocytes |
| Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
| Reacting condition | 10 µM, 24 hours |
| Applications | No evidence of apoptosis or necrosis was detected in lymphocytes exposed to CI994 for 4 hours. After 24 hours, concentration-dependent increases in apoptosis characterized by DNA condensation, DNA fragmentation, and/or externalization of phosphatidyl serine were seen at CI-994 concentrations as low as 1 µM and were statistically significant beginning at 10 µM. |
| Animal experiment: [2] | |
| Animal models | Male Wistar rats |
| Dosage form | Oral administration, 45 mg/kg |
| Application | 15 rats per group were administered a single dose of CI994 at 0 (vehicle control), 10, 23, and 45 mg/kg. 5 rats per group were killed 1, 3, and 7 days after dosing for evaluation of blood and bone marrow lymphocyte counts. CI994 treatments resulted in significant dose-related reductions in total white blood cell counts, total lymphocytes and lymphocyte subpopulations. Relative to controls, reductions on day 1 ranged from 36 to 48% at 10 mg/kg, 65 to 76% at 23 mg/kg, and 74 to 87%at 45 mg/kg. Dose-related reductions in monocytes ranging from 54 to 89% were observed in all drug-treated groups on days 1 and 3. Besides that, significant dose-related reductions in bone marrow lymphoid cells ranged from 28 to 33% at 10 mg/kg, 63 to 69%at 23 mg/kg, and 80 to 87%at 45 mg/kg. |
| Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| References: [1] Graziano M J, Spoon T A, Cockrell E A, et al. Induction of apoptosis in rat peripheral blood lymphocytes by the anticancer drug CI-994 (acetyldinaline). BioMed Research International, 2001, 1(2): 52-61. [2] Graziano M J, Galati A J, Walsh K M. Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue. Archives of toxicology, 1999, 73(3): 168-174. | |
CI994 (Tacedinaline) Dilution Calculator
CI994 (Tacedinaline) Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.7133 mL | 18.5667 mL | 37.1333 mL | 74.2666 mL | 92.8333 mL |
| 5 mM | 0.7427 mL | 3.7133 mL | 7.4267 mL | 14.8533 mL | 18.5667 mL |
| 10 mM | 0.3713 mL | 1.8567 mL | 3.7133 mL | 7.4267 mL | 9.2833 mL |
| 50 mM | 0.0743 mL | 0.3713 mL | 0.7427 mL | 1.4853 mL | 1.8567 mL |
| 100 mM | 0.0371 mL | 0.1857 mL | 0.3713 mL | 0.7427 mL | 0.9283 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
CI994 is a selective inhibitor of HDAC1 with IC50 value of 0.57 μM [1].
HDAC1 is an enzyme that encoded by HDAC1 and plays a pivotal role in regulating eukaryotic gene expression. It is also been reported that HDAC1 interacts with retinoblastoma tumor-suppressor protein which is a key element in the control of cell proliferation and differentiation. Many studies have shown that HDAC1 inhibition works as a promising therapy used for cancer treatment in clinic [2] [3].
CI994 is a selective HDAC1 and HDAC3 and is different from the reported unselective inhibitor SAHA. When tested with HeLa cervical carcinoma cells, CI994 treatment showed a selectivity inhibitory ability for HDAC1 and 3 with the IC50 was 43.5±1.2 μM [4]. In peripheral blood lymphocytes isolated from untreated male Wistar rats, administration of CI994 for 24 hours induced cells apoptosis in a dose-dependent manner (1 μM~10μM ) [1]. When tested with mitogen-stimulated blood lymphocytes, CI-994 treatment inhibited cells proliferation with IC50 value of 3 mM [5]. In NSCLC cell lines (A549 and LX-1), CI994 administration induced cell apoptosis via inhibiting HDAC activity and arresting cell cycle at G0/G1 phase and showed a promising therapy strategy when combined with chemotherapy [2].
In male rats model, oral administration of CI994 markedly effected lymphoid tissue via reducing blood lymphocytes, monocytes, neutrophils and bone marrow lymphoid cells at the concentration of 10, 23, and 45 mg/kg on day 1 and/or 3 [5].
References:
[1]. Graziano, M.J., et al., Induction of Apoptosis in Rat Peripheral Blood Lymphocytes by the Anticancer Drug CI-994 (Acetyldinaline)(*). J Biomed Biotechnol, 2001. 1(2): p. 52-61.
[2]. Loprevite, M., et al., In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res, 2005. 15(1): p. 39-48.
[3]. Cacan, E., et al., Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance. PLoS One, 2014. 9(1): p. e87455.
[4]. Beckers, T., et al., Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer, 2007. 121(5): p. 1138-48.
[5]. Graziano, M.J., A.J. Galati, and K.M. Walsh, Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue. Arch Toxicol, 1999. 73(3): p. 168-74.
- Citrusinol
Catalog No.:BCN8083
CAS No.:112516-43-5
- Tubuloside A
Catalog No.:BCN2806
CAS No.:112516-05-9
- Neolinine
Catalog No.:BCN6564
CAS No.:112515-37-4
- Isoabsouline
Catalog No.:BCN1955
CAS No.:112513-34-5
- Absouline
Catalog No.:BCN1954
CAS No.:112513-33-4
- Picrasidine S
Catalog No.:BCN6006
CAS No.:112503-87-4
- Aristolactam FI
Catalog No.:BCN6005
CAS No.:112501-42-5
- 6-Aldehydo-isoophiopogonone A
Catalog No.:BCN6629
CAS No.:112500-90-0
- 5-Aminoisoquinoline
Catalog No.:BCC8736
CAS No.:1125-60-6
- 4,4-Pentamethylenepiperidine hydrochloride
Catalog No.:BCC6059
CAS No.:1125-01-5
- H-Glu(OcHex)-OH
Catalog No.:BCC2929
CAS No.:112471-82-6
- U-54494A hydrochloride
Catalog No.:BCC6668
CAS No.:112465-94-8
- ent-16alpha,17-Dihydroxyatisan-3-one
Catalog No.:BCN6607
CAS No.:112523-91-8
- Pioglitazone HCl
Catalog No.:BCC2278
CAS No.:112529-15-4
- 4-O-Methylepisappanol
Catalog No.:BCN3674
CAS No.:112529-37-0
- Mps1-IN-1
Catalog No.:BCC5590
CAS No.:1125593-20-5
- A 804598
Catalog No.:BCC6198
CAS No.:1125758-85-1
- SKLB610
Catalog No.:BCC3647
CAS No.:1125780-41-7
- 4-Allylpyrocatechol
Catalog No.:BCN6009
CAS No.:1126-61-0
- Iso-mogroside V
Catalog No.:BCN3047
CAS No.:1126032-65-2
- Dicyclanil
Catalog No.:BCC8938
CAS No.:112636-83-6
- U-73122
Catalog No.:BCC5199
CAS No.:112648-68-7
- Garcinone E
Catalog No.:BCN3604
CAS No.:112649-21-5
- BR-Xanthone A
Catalog No.:BCN6007
CAS No.:112649-48-6
